Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Provided By GlobeNewswire
Last update: Oct 30, 2024
Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months
Consistent reductions across CSF tau biomarkers and tau PET in majority of participants
Read more at globenewswire.com3.21
+0.5 (+18.45%)
Find more stocks in the Stock Screener
LXEO Latest News and Analysis
12 days ago - ChartmillWhich stocks are moving on Wednesday?Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session.
14 days ago - ChartmillWhich stocks are moving on Monday?Here are the top movers in Monday's session, showcasing the stocks with significant price changes.
14 days ago - ChartmillKeep an eye on the top gainers and losers in Monday's session.Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.
15 days ago - ChartmillMonday's session: gap up and gap down stocksThe market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
